• eTheRNA
  • Empowering the human immune system with targeted and safe mRNA therapies to help patients fight cancer and infectious diseases

Scientific advisory board

The Scientific Advisory Board of eTheRNA immunotherapies includes some of the world’s most renowned experts in the field of immunology, oncology and immune-oncology. The Scientific Advisory Board is a neutral body that assists the management team in scientifically guiding the company and that provides feedback and advice at each development stage of the company’s R&D pipeline.

The board consists of:

Pierre Coulie

Pierre Coulie
Dr. Pierre Coulie MD PhD is full professor at the Université Catholique de Louvain (UCL), Louvain/Belgium. Dr. Coulie is trained as an immunologist in murine rheumatoid factor and cytokines. In 1988, he joined the team of tumor immunologists headed by Thierry Boon. From 1989 to 1995, he was investigator at the Brussels branch of the Ludwig Institute. Dr. Coulie contributed to the identification of several human tumor-specific antigens recognized by T lymphocytes. He is primarily interested human anti-tumor immunology in the context of immunotherapy, focusing on spontaneous antitumor immune responses in cancer patients and reasons for the absence or loss of tumor control, antigenicity of tumors, mechanics of tumor resistance to currently available immunotherapies, predictive biomarkers in cancer immunotherapy, and immunization against tumor-specific antigens.

Leisha An Emens

Leisha An Emens
Leisha A. Emens, MD, PhD, is an Associate Professor of Oncology at the Kimmel Cancer Center at the Johns Hopkins University School of Medicine. Dr. Emens is board certified in both internal medicine and medical oncology. She is a member of the newly established Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and a member of the Cancer Immunology and the Breast and Ovarian Cancer research programs. Dr. Emens is a practicing medical oncologist and runs a research laboratory focused on translational immunotherapy for both breast and ovarian cancers. She is internationally recognized for her work in developing innovative combination immunotherapies that incorporate cancer vaccines, immune checkpoint inhibitors, and other immune modulators with standard and novel treatments for breast cancer. Dr. Emens is on the Board of Directors for the Society for the Immunotherapy of Cancer (SITC), and is section editor for the Journal for the Immunotherapy of Cancer (JITC). Dr. Emens is also on the editorial board of Cancer Research, the Breast Journal. She is an active member of ASCO, AACR, and SITC and is a member of the Cancer Immunology (CIMM) Working Group of the AACR.

Aurélien Marabelle

Aurélien Marabelle
Dr. Aurélien Marabelle MD PhD is the clinical director of the cancer immunotherapy program at Gustave Roussy Cancer Center in Villejuif, France. Dr. Marabelle’s clinical practice is dedicated to early phase clinical trials in cancer immunotherapy. His translational research is focused on mechanisms of action of immune checkpoint monoclonal antibodies. He works as a senior medical oncologist and an investigator in the Drug Development Department (DITEP) directed by Prof. Jean-Charles Soria. He is coordinating a team focusing on cancer immunotherapy translational research projects in the INSERM U1015 lab directed by Prof. Laurence Zitvogel. Dr. Marabelle is a member of ESMO, ASCO, EATI & AACR.

Bart Neyns

Bart Neyns
Dr. Bart Neyns MD PhD is clinical professor at the Vrije Universiteit Brussel (VUB) and head of division at the department of Internal Medicine/ Medical Oncology at the university hospital UZ Brussel, Brussels/Belgium. He is also Dermato-Oncology consultant at the Erasme Hospital Université Libre de Bruxelles (ULB), Brussels. Dr. Neyns was principal investigator for more than ten academia sponsored clinical trials in various areas, including advanced melanoma, glioma and colorectal cancer - several of these focusing on a proprietary autologous dendritic cell therapy. His current research interests include the immune- and targeted therapy of melanoma and the treatment of patients with malignant glioma. Dr Neyns is the member of seven national and international scientific societies including, the Belgian Medical Society of Medical Oncology ESMO, ASCO and AACR.

Caetano Reis E Sousa

Caetano Reis E Sousa
Dr. Caetano Reis e Sousa DPhil is head of the Immunobiology laboratory and Senior Group Leader at the Francis Crick Institute, London (UK He is also Professor of Immunology in the Department of Medicine at Imperial College and holds honorary professorships at University College London and King’s College London. Dr. Reis e Sousa’s research centres on the regulation of adaptive immunity by antigen-presenting cells, the innate immune mechanisms involved in sensing pathogen presence and cell death and the complexity of the mononuclear phagocyte system. His scientific contributions have been widely recognised and he was elected a member of the European Molecular Biology Organisation (EMBO) in 2006, a fellow of The Academy of Medical Sciences in the same year and was made an Officer of the Order of Sant’Iago da Espada by his native Portugal in 2009. He is included in the list of Highly Cited Researchers (Thomson Reuters) and has won the BD Biosciences Prize of the European Macrophage and Dendritic Cell Society (2002), the Liliane Bettencourt for Life Sciences Award (2008), the Award for Excellence in Basic/Translational Research from the European Society for Clinical Investigation (2011) and the Louis-Jeantet Prize for Medicine (2017).

Pedro Romero

Pedro Romero
Pedro Romero MD is Professor at the Faculty of Biology and Medicine, University of Lausanne where he also heads the Department of Fundamental Oncology at the Ludwig Cancer Research Center. Prior to joining the Lausanne branch of the Ludwig Institute for Cancer Research in 1989, Dr. Romero conducted research at the Department of Medical and Molecular Parasitology at New York University School of Medicine . Dr. Romero holds a number of patents and has published more than 270 articles, describing his scientific works in peptide based immunotherapy, several of them in “Science” or “Nature”. In 2001, he won the Robert Wenner prize from the Swiss Cancer League on Applied Cancer Research, to complement other honors he received. Dr. Romero‘s research interests include cancer vaccines, lymphocyte differentiation and the understanding of antigen specific T cell responses. He currently serves as the editor-in-chief of the Journal for Immunotherapy of Cancer.

Walter Urba

Walter Urba
Dr. Walter Urba MD PhD is board-certified in oncology and internal medicine, specializing in clinical research and in the care of patients with melanoma. He has 30 years of experience in the development of immunotherapy. Dr. Urba is an affiliate investigator in the division of clinical research at the Fred Hutchinson Cancer Research Center in Seattle (US). He has served on several oversight committees and advisory boards focused on cancer immunology and immunotherapy, including the melanoma, immunomolecular and genitourinary committees with Southwest Oncology Group of the University of Arizona (US); the cellular, tissue and gene therapies advisory committee of the Food and Drug Administration; and the NCI board of scientific counselors for clinical studies and epidemiology. Dr. Urba also serves on various editorial boards, including of the Journal of Immunotherapy and The Oncologist.

Michael von Euler

Michael Von Euler
Dr. Mikael von Euler, M.D., PhD., FFPM, serves as the Chief Medical Officer and Vice President of Clinical Development of Aprea AB, a Karolinska Development portfolio company , as Chairman of the Clinical Advisory Board of Oncos Therapeutics Ltd. and as Clinical Adviser of Targovax ASA. He is a clinical development professional and a seasoned oncology executive, with more than twenty years of pharmaceutical industry experience in senior roles, being involved in bringing around fifteen new pharmaceutical products to the market. At Roche (2007-2010), Dr. von Euler held global clinical responsibility for the HER family of compounds including Herceptin, Pertuzumab and Tarceva, and acted as a Cluster Head for the HER2 Franchise. Prior to Roche, Mikael was Vice President, Oncology MDC, Europe, at GlaxoSmithKline and worked across several key clinical development roles at AstraZeneca.